Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant
Saurabh S. Kokane, Ross J. Armant, Carlos A. Bolaños‐Guzmán, et al.
Behavioural Brain Research (2020) Vol. 384, pp. 112548-112548
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up
Natalie Gukasyan, Alan K. Davis, Frederick S. Barrett, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 2, pp. 151-158
Open Access | Times Cited: 296
Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials
Joanna Kryst, Paweł Kawalec, Alicja Mikrut Mitoraj, et al.
Pharmacological Reports (2020) Vol. 72, Iss. 3, pp. 543-562
Open Access | Times Cited: 111
Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature
Giovanni Martinotti, Stefania Chiappini, Mauro Pettorruso, et al.
Brain Sciences (2021) Vol. 11, Iss. 7, pp. 856-856
Open Access | Times Cited: 86
Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment
Jenessa N. Johnston, Bashkim Kadriu, Josh Allen, et al.
Neuropharmacology (2023) Vol. 226, pp. 109422-109422
Open Access | Times Cited: 32
Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING)
Mauro Pettorruso, Roberto Guidotti, Giacomo d’Andrea, et al.
Psychiatry Research (2023) Vol. 327, pp. 115378-115378
Open Access | Times Cited: 22
Changes in white matter microstructure following serial ketamine infusions in treatment resistant depression
Brandon Taraku, Roger P. Woods, Michael Boucher, et al.
Human Brain Mapping (2023) Vol. 44, Iss. 6, pp. 2395-2406
Open Access | Times Cited: 16
Molecular Mechanisms of Reelin in the Enteric Nervous System and the Microbiota–Gut–Brain Axis: Implications for Depression and Antidepressant Therapy
Ciara S. Halvorson, Carla L. Sánchez-Lafuente, Jenessa N. Johnston, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 814-814
Open Access | Times Cited: 6
Use and abuse of dissociative and psychedelic drugs in adolescence
M.L. Shawn Bates, Keith A. Trujillo
Pharmacology Biochemistry and Behavior (2021) Vol. 203, pp. 173129-173129
Open Access | Times Cited: 40
Comorbidity of ketamine dependence with major depressive disorder increases the vulnerability to neuroaxonal pathology
Ming‐Chyi Huang, Chun‐Hsin Chen, Tung‐Hsia Liu, et al.
Journal of Psychiatric Research (2023) Vol. 158, pp. 360-364
Closed Access | Times Cited: 14
Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review
Matteo Di Vincenzo, Vassilis Martiadis, Bianca Della Rocca, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 5
Increased Sensitivity to Psychomotor Effects of Ketamine Enantiomers in the Wistar-Kyoto Depression Model
Kristian Elersič, Anamarija Banjac, Marko Živin, et al.
Journal of Psychiatric Research (2025) Vol. 184, pp. 307-317
Open Access
PROPHYLACTIC KETAMINE: CURRENT KNOWLEDGE AND FUTURE DIRECTIONS
Astrid M. Cardona-Acosta, Lyonna F. Parise, Carlos A. Bolaños‐Guzmán, et al.
Biological Psychiatry (2025)
Closed Access
Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence
Nelson B. Rodrigues, Roger S. McIntyre, Orly Lipsitz, et al.
Journal of Affective Disorders (2020) Vol. 276, pp. 570-575
Closed Access | Times Cited: 38
Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression
Alina Wilkowska, Mariusz S. Wiglusz, Maria Gałuszko‐Węgielnik, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 28
Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study
Sagar V. Parikh, Scott T. Aaronson, Sanjay J. Mathew, et al.
Neuropsychopharmacology (2023) Vol. 49, Iss. 2, pp. 467-475
Open Access | Times Cited: 11
Role of the mesolimbic dopamine pathway in the antidepressant effects of ketamine
Astrid M. Cardona-Acosta, Carlos A. Bolaños‐Guzmán
Neuropharmacology (2022) Vol. 225, pp. 109374-109374
Open Access | Times Cited: 16
Age, Dose, and Locomotion: Decoding Vulnerability to Ketamine in C57BL/6J and BALB/c Mice
Wen-Chien Chen, Tzong‐Shi Wang, Fang‐Yu Chang, et al.
Biomedicines (2023) Vol. 11, Iss. 7, pp. 1821-1821
Open Access | Times Cited: 9
Behavioral sensitization and tolerance induced by repeated treatment with ketamine enantiomers in male Wistar rats
Kristian Elersič, Anamarija Banjac, Marko Živin, et al.
PLoS ONE (2024) Vol. 19, Iss. 3, pp. e0299379-e0299379
Open Access | Times Cited: 3
Repurposing of Drugs–The Ketamine Story
Joydip Das
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 22, pp. 13514-13525
Closed Access | Times Cited: 24
Neurofilament light chain as novel blood biomarker of disturbed neuroaxonal integrity in patients with ketamine dependence
Yu‐Li Liu, Francesco Bavato, Annie Chung, et al.
The World Journal of Biological Psychiatry (2021) Vol. 22, Iss. 9, pp. 713-721
Open Access | Times Cited: 20
Gray matter volume of rostral anterior cingulate cortex predicts rapid antidepressant response to ketamine
Ana Lucía Herrera-Meléndez, Anna Stippl, Sabine Aust, et al.
European Neuropsychopharmacology (2020) Vol. 43, pp. 63-70
Closed Access | Times Cited: 23
Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects
Tuyen T. Le, Joshua D. Di Vincenzo, Kayla M. Teopiz, et al.
Psychiatry Research (2021) Vol. 306, pp. 114231-114231
Closed Access | Times Cited: 19
2‐Fluorodeschloroketamine has similar abuse potential as ketamine
Feng Li, Han Du, Bo Wu, et al.
Addiction Biology (2022) Vol. 27, Iss. 3
Closed Access | Times Cited: 12
Time-dependent antidepressant-like effects of reelin and ketamine in the repeated-corticosterone model of chronic stress
Kaylene Scheil, Carla L. Sánchez-Lafuente, Brady S. Reive, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2024) Vol. 132, pp. 110998-110998
Closed Access | Times Cited: 2
Ketamine beyond anesthesia: Antidepressant effects and abuse potential
Keith A. Trujillo, Sergio D. Iñiguez
Behavioural Brain Research (2020) Vol. 394, pp. 112841-112841
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top